Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease

Journal of Neurochemistry

Volumn 115, Issue 1, 2010, Pages 188-199

  Xie, Wenjie ^a   Li, Xuping ^a   Li, Chao ^a   Zhu, Wen ^a   Jankovic, Joseph ^a   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

dopamine neuron degeneration; lactacystin; Parkinson's disease animal model; proteasome inhibition; UPS impairment

Indexed keywords

ALPHA SYNUCLEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; LACTACYSTIN; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; ACETYLCYSTEINE; DOPAMINE; IRON; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME INHIBITION; LOCOMOTION; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CELL COUNT; CHEMICALLY INDUCED; ELECTRON MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROINJECTION; NERVE CELL; PATHOLOGY; PHYSIOLOGY; TOXICITY; WESTERN BLOTTING;

ANIMALIA; MUS;

ACETYLCYSTEINE; ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; IRON; MALE; MICE; MICE, INBRED C57BL; MICROINJECTIONS; MICROSCOPY, ELECTRON; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; SUBSTANTIA NIGRA; UBIQUITIN;

EID: 77956596883     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06914.x     Document Type: Article

References (51)

1. Anastasía A., Torre L. de Erausquin G. A. et al. (2009) Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease. J. Neurochem. 109, 755 765.
2. Baqueta Z. C., Williamsa D. Brodya J. et al. (2009) A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161, 1082 1090.
3. Beal F. Lang A. (2006) The proteasomal inhibition model of Parkinson's disease: "boon or bust"? Ann. Neurol. 60, 158 161.
4. Bedford L., Hay D., Devoy A. et al. (2008) Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 28, 8189 8198.
5. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H. J., Wu D. C., Kordower J. H., Petrucelli L. Przedborski S. (2006) Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 60, 260 264.
6. Bretaud S., Allen C., Ingham P. W. Bandmann O. (2007) p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J. Neurochem. 100, 1625 1635.
7. Brooks S. P. Dunnett S. B. (2009) Tests to assess motor phenotype in mice: a user's guide. Nat. Rev. Neurosci. 10, 519 529.
8. Caldwell K. A., Tucci M. L., Armagost J. et al. (2009) Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration. PLoS ONE 4, e7227.
9. Chesselet M. F. (2008) In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp. Neurol. 209, 22 27.
10. Dick L. R., Cruikshank A. A. Grenier L. et al. (1996) Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J. Biol. Chem. 271, 7273 7276.
11. Ekstrand M. I., Terzioglu M., Galter D. et al. (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl Acad. Sci. USA 104, 1325 1330.
12. Emborg M. E. (2004) Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Methods 139, 121 143.
13. Fleming S. M. Chesselet M. F. (2006) Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behav. Pharmacol. 17, 383 391.
14. Fornai F., Lenzi P., Gesi M. et al. (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23, 8955 8966.
15. Gupta A., Dawson V. L. Dawson T. M. (2008) What causes cell death in Parkinson's disease? Ann. Neurol. 64, S3 S15.
16. Hirsch E. C. Hunot S. (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8, 382 397.
17. Jankovic J., Chen S. Le W. D. (2005) The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog. Neurobiol. 77, 128 138.
18. Jenner P. (2008) Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann. Neurol. 64, S16 S29.
19. Kim J., Inoue K., Ishii J., Vanti W. B., Voronov S. V., Murchison E., Hannon G. Abeliovich A. (2007) A Micro-RNA feedback circuit in midbrain dopamine neurons. Science 317, 1220 1224.
20. Le W., Chen S. Jankovic J. (2009) Etiopathogenesis of Parkinson's disease: a new beginning? Neuroscientist 15, 28 35.
21. Levy O. A., Malagelada C. Greene L. A. (2009) Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 14, 478 500.
22. Li X., Yang D., Li L., Peng C., Chen S. Le W. (2007) Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures. Neurochem. Int. 50, 959 965.
23. Li X., Du Y., Fan X., Yang D., Luo G. Le W. (2008) c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration. J. Neuropathol. Exp. Neurol. 67, 933 944.
24. Li Y., Liu W., Oo T. F. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 12, 826 828.
25. Li C., Guo Y., Xie W., Li X. G., Janokovic J. Le W. (2010) Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Neurochem. Res. [Epub ahead of print].
26. Lim K. L. (2007) Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies. Exp. Rev. Proteom. 4, 769 781.
27. Manning-Bog A. B., Reaney S. H., Chou V. P., Johnston L. C., McCormack A. L., Johnston J., Langston J. W. Di Monte D. A. (2006) Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 60, 256 260.
28. McNaught K. S. Olanow C. W. (2006) Protein aggregation in the pathogenesis of familiar and sporadic Parkinson's disease. Neurobiol. Aging 27, 530 545.
29. McNaught K. S., Björklund L. M., Belizaire R., Isacson O., Jenner P. Olanow C.W. (2002) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13, 1437 1441.
30. McNaught K. S., Perl D. P., Brownell A. L. Olanow C. W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56, 149 162.
31. Meredith G. E. Kang U. K. (2006) Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov. Disord. 21, 1595 1606.
32. Meredith G. E., Sonsalla P. K. Chesselet M. F. (2008) Animal models of Parkinson's disease progression. Acta Neuropathol. 115, 385 398.
33. Miwa H., Kubo T., Suzuki A., Nishi K. Kondo T. (2005) Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci. Lett. 380, 93 98.
34. Nair V. D., McNaught K. S., González-Maeso J., Sealfon S. C. Olanow C. W. (2006) p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 281, 39550 39560.
35. Olanow C. W. Kordower J. H. (2009) Modeling Parkinson's disease. Ann. Neurol. 66, 432 436.
36. Outeiro T. F., Kontopoulos E., Altmann S. M. et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516 519.
37. Pan T., Kondo S., Zhu W., Xie W., Jankovic J. Le W. (2008) Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol. Dis. 32, 16 25.
38. Paxinos G. Franklin K. B. (2001) The Mouse Brain in Stereotaxic Coordinations, 2nd edn. Academic Press, San Diego, CA.
39. Petrucelli L. Dawson T. M. (2004) Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann. Med. 36, 315 320.
40. Reaney S. H., Johnston L. C., Langston W. J. Di Monte D. A. (2006) Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp. Neurol. 202, 434 440.
41. Rideout H. J., Lang-Rollin I. C., Savalle M. Stefanis L. (2005) Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem. 93, 1304 1313.
42. Shahbazian M., Young J., Yuva-Paylor L., Spencer C., Antalffy B., Noebels J., Armstrong D., Paylor R. Zoghbi H. (2002) Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35, 243 254.
43. Sun F., Anantharam V., Zhang D., Latchoumycandane C., Kanthasamy A. Kanthasamy A. G. (2006) Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 27, 807 815.
44. Taylor T. N, Caudle W. M., Shepherd K. R., Noorian A., Jackson C. R., Iuvone P. M., Weinshenker D., Greene J. G. Miller G. W. (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29, 8103 8113.
45. Terzioglu M. Galter D. (2008) Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J. 275, 1384 1391.
46. Tinsley R. B., Bye C. R., Parish C. L., Tziotis-Vais A., George S., Culvenor J. G., Li Q. X., Masters C. L., Finkelstein D. I. Horne M. K. (2009) Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann. Neurol. 66, 472 484.
47. Vernon A. C., Johansson S. M. Modo M. M. (2010) Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neurosci. 11, 1 18.
48. Yacoubian T. A. Standaert D. G. (2009) Targets for neuroprotection in Parkinson's disease. Biochim. Biophys. Acta 1792, 676 687.
49. Zhang X., Xie W., Qu S., Pan T., Wang X. Le W. (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun. 333, 544 549.
50. Zhou Z., Kerk S. Meng Lim T. (2008) Endogenous dopamine (DA) renders dopaminergic cells vulnerable to challenge of proteasome inhibitor MG132. Free Radic. Res. 42, 456 466.
51. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M. B. Le W. (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 21, 3835 3844.